BRAF and colorectal cancer: A further difference between BRAF-mutated melanoma and colorectal cancer is that BRAF-mutated colorectal cancer cells possess higher levels of PI3K activation than BRAF-mutated melanoma cells, and that resistance to vemurafenib could be overcome by combining vemurafenib with PI3K inhibitors [58–60].